Q3 2025 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2025-11-14 · accession 0001937964-25-000008
$630.9M
Reported value
51
Positions
2025-09-30
Period end
The Brief · Artia Global Partners LP · Q3 2025
AI · grounded in 13F
Artia Global Partners LP established a new position in INSM valued at $163.0M. The fund also initiated new stakes in ARGX for $57.8M and SLNO for $45.4M. Other new additions include VRNA at $40.4M and QURE at $38.5M. The fund ended the period with 48 positions and total AUM of $630.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $105.4M | 16.7% | 732,212 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $57.8M | 9.16% | 78,311 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $57.6M | 9.13% | 400,000 | CALL | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $45.4M | 7.20% | 672,176 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $40.4M | 6.41% | 379,004 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $38.5M | 6.10% | 658,839 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $27.9M | 4.43% | 296,750 | Common | SOLE |
| 74347W601 | UGL | PROSHARES TR II | $24.8M | 3.92% | 537,372 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $21.9M | 3.47% | 28,700 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $21.6M | 3.42% | 55,100 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $19.1M | 3.03% | 225,453 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $18.3M | 2.90% | 1,999,702 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $17.9M | 2.84% | 183,200 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $15.8M | 2.50% | 34,570 | Common | SOLE |
| 74834L100 | DGX | QUEST DIAGNOSTICS INC | $15.6M | 2.47% | 81,717 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $14.6M | 2.32% | 190,752 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $8.9M | 1.42% | 628,367 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $6.0M | 0.95% | 10,671 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $5.5M | 0.88% | 194,838 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.9M | 0.77% | 104,190 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $4.8M | 0.76% | 110,100 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $4.5M | 0.72% | 150,000 | CALL | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $4.3M | 0.68% | 108,723 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $3.9M | 0.62% | 60,176 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $3.8M | 0.61% | 146,179 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $3.6M | 0.57% | 96,285 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $3.4M | 0.53% | 14,500 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $3.3M | 0.52% | 57,999 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.2M | 0.51% | 133,291 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $2.4M | 0.39% | 12,240 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $2.1M | 0.34% | 56,600 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.1M | 0.33% | 5,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $2.0M | 0.31% | 54,515 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $1.9M | 0.31% | 64,502 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $1.9M | 0.30% | 64,608 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $1.6M | 0.26% | 141,061 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.6M | 0.25% | 40,000 | Common | SOLE |
| Q4982L109 | IREN | IREN LIMITED | $1.6M | 0.25% | 33,200 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $1.5M | 0.24% | 22,951 | Common | SOLE |
| 10950A106 | BTSG | BRIGHTSPRING HEALTH SVCS INC | $1.2M | 0.19% | 41,600 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $1.2M | 0.19% | 80,000 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $1.1M | 0.18% | 29,200 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.1M | 0.17% | 20,400 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $979,244 | 0.16% | 475,361 | Common | SOLE |
| 830607100 | — | SAREPTA THERAPEUTICS INC | $865,223 | 0.14% | 44,900 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $738,510 | 0.12% | 30,900 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $614,754 | 0.10% | 23,800 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $506,140 | 0.08% | 41,555 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $432,840 | 0.07% | 600,000 | CALL | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $268,560 | 0.04% | 372,276 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $210,246 | 0.03% | 71,029 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.